STAGE III CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AJCC V8
Clinical trials for STAGE III CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Cancer vaccine plus immunotherapy shows promise in Hard-to-Treat cancers
Disease control OngoingThis study combines the CIMAvax EGF vaccine with immunotherapy drugs (nivolumab or pembrolizumab) to treat advanced non-small cell lung cancer and squamous head and neck cancer. The vaccine aims to slow tumor growth, while the immunotherapy helps the immune system attack cancer c…
Matched conditions: STAGE III CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Immunotherapy drug may save eyes from aggressive skin cancer
Disease control OngoingThis study tests whether the immunotherapy drug pembrolizumab can shrink or control advanced or recurrent skin cancer near the eye. About 22 adults with this condition will receive the drug. The goal is to see if the cancer responds and if the eye can be saved from surgery.
Matched conditions: STAGE III CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AJCC V8
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a Three-Pronged attack shrink Hard-to-Treat head and neck cancers?
Disease control OngoingThis phase I trial is testing whether a combination of three treatments — an experimental drug called elimusertib, precise radiation therapy, and the immunotherapy pembrolizumab — can shrink or stabilize recurrent head and neck cancer that cannot be removed by surgery. The study …
Matched conditions: STAGE III CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Immunotherapy before surgery shows promise for head and neck cancer
Disease control OngoingThis phase II trial is testing whether giving the immunotherapy drug cemiplimab before surgery can help shrink tumors in people with stage II to IV head and neck skin cancer that can be removed. The study enrolled 44 participants and aims to see how many respond to the drug. If i…
Matched conditions: STAGE III CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC